GlassScriptPhysician profile
Sharon L Doering
NPI 1760459317
$10,140.89
in general payments reported to CMS, 2019-2025
29 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $849 · 2022: $1,711 · 2023: $3,247 · 2024: $2,906 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,486 · Consulting Fee: $2,988 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,485.92 |
| Consulting Fee | $2,987.50 |
| Education | $107.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,703.36 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,227.27 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,071.31 | 2023-2024 | Cabtreo, Siliq, Targretin |
| Incyte Corporation | $1,048.85 | 2023-2025 | Opzelura |
| Epi Health, LLC | $843.63 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $659.33 | 2021-2025 | Winlevi, Ilumya |
| Leo Pharma INC. | $581.24 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $474.18 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $468.83 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Ucb, INC. | $275.36 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $273.96 | 2021-2024 | Tremfya, Remicade, Simponi |
| Genzyme Corporation | $270.24 | 2021-2024 | |
| Amgen INC. | $172.27 | 2021-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $164.14 | 2021-2025 | |
| Organon LLC | $120.30 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.12 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $100.98 | 2023-2024 | Vtama |
| Lilly USA, LLC | $90.11 | 2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $80.43 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.00 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $79.14 | 2021-2024 | |
| Almirall LLC | $70.54 | 2022-2025 | Seysara |
| Sanofi-Aventis U.S. LLC | $59.38 | 2021 | |
| Journey Medical Corporation | $26.47 | 2025 | |
| Bard Peripheral Vascular, INC. | $18.09 | 2024 | Venclose Maven Catheter |
| Botanix Sb INC | $17.71 | 2025 | Sofdra |
| Genentech USA, INC. | $16.43 | 2021 | |
| Kyowa Kirin, INC. | $15.30 | 2025 | |
| Hydrofera LLC | $14.92 | 2024 | Hydrofera Blue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Doering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.